Aphria Inc. (" Aphria " or the " Company ") ( TSX: APHA and NYSE: APHA ) today announced that its German subsidiary Aphria Deutschland GmbH (" Aphria Germany ") has been selected by the German Federal Institute for Drugs and Medical Devices (" BfArM ") to receive a license for the domestic cultivation of medical cannabis. The provisional decision announced by BfArM is subject to a mandatory 10-day standstill period for public contracts (the " Standstill "), which permits unsuccessful bidders to challenge the decision before the final contract is signed. BfArM's decision would grant Aphria 5 of the 13 available lots, each with a minimum annual capacity of 200 kg.